{"id":22813,"date":"2022-01-11T13:11:00","date_gmt":"2022-01-11T13:11:00","guid":{"rendered":"https:\/\/celonpharma.com\/?p=22813"},"modified":"2022-01-18T13:13:53","modified_gmt":"2022-01-18T13:13:53","slug":"current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/","title":{"rendered":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 inside information.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">January 11, 2021, 08:46 PM<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In reference to current report No. 52\/2021, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in \u201cEuropean Patent Bulletin 21\/49\u201d of December 8, 2021.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In accordance with the received specification, Patent No. EP 3 731 815 B1 concerns a pharmaceutical composition in the form of a dry powder, containing ketamine or its pharmaceutically acceptable salt, to be used to treat depression by direct pulmonary administration, whereas the scope of Patent EP 3 505 157 B1 is broader and involves using a pharmaceutical composition in the form of a dry powder, containing ketamine or its pharmaceutically acceptable salt, in a drug suitable for pulmonary administration, without being restricted solely to the treatment of treatment-resistant depression.<br>It might create possibilities for using it in developing drugs for other indications in this therapeutic area.<br>In the opinion of the Management Board, such a broad patent protection increases the value of potential commercialization of the Company\u2019s products within the therapeutic areas covered by the protection.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In reference to current report No. 52\/2021, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in \u201cEuropean Patent Bulletin 21\/49\u201d of December 8, 2021.<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[46],"tags":[],"class_list":["post-22813","post","type-post","status-publish","format-standard","hentry","category-current-reports"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"In reference to current report No. 52\/2021, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in \u201cEuropean Patent Bulletin 21\/49\u201d of December 8, 2021.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-11T13:11:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-18T13:13:53+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"Current report No. 2\\\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression\",\"datePublished\":\"2022-01-11T13:11:00+00:00\",\"dateModified\":\"2022-01-18T13:13:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/\"},\"wordCount\":217,\"articleSection\":[\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/\",\"name\":\"Current report No. 2\\\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2022-01-11T13:11:00+00:00\",\"dateModified\":\"2022-01-18T13:13:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current report No. 2\\\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/","og_locale":"en_US","og_type":"article","og_title":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma","og_description":"In reference to current report No. 52\/2021, the Management Board of Celon Pharma S.A. (\u201cCompany\u201d) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in \u201cEuropean Patent Bulletin 21\/49\u201d of December 8, 2021.","og_url":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/","og_site_name":"Celon Pharma","article_published_time":"2022-01-11T13:11:00+00:00","article_modified_time":"2022-01-18T13:13:53+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression","datePublished":"2022-01-11T13:11:00+00:00","dateModified":"2022-01-18T13:13:53+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/"},"wordCount":217,"articleSection":["Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/","url":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/","name":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2022-01-11T13:11:00+00:00","dateModified":"2022-01-18T13:13:53+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/current-report-no-2-2022-obtaining-information-concerning-a-european-patent-for-esketamine-inhalation-formulation-and-expanding-patent-protection-beyond-the-treatment-of-treatment-resistant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Current report No. 2\/2022 \u2013 Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=22813"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22813\/revisions"}],"predecessor-version":[{"id":22815,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/22813\/revisions\/22815"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=22813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=22813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=22813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}